

Neoadjuvant and Adjuvant Treatment in Early-Stage NSCLC: Options Are Expanding – Clinical Brief #3

References

Tweet 2

Akhdar M, Syaj S, Alser O, Elshami M, Hamouri S. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for patients with stage III-N2M0 non-small cell lung cancer (NSCLC): A population-based study. *J Clin Oncol*. 2022;40(16_suppl):8503. doi:10.1200/JCO.2022.40.16_suppl.8503

O'Brien MER, Paz-Ares L, Jha N, et al. EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. *J Clin Oncol*. 2022;40(16_suppl):8512. doi:10.1200/JCO.2022.40.16_suppl.8512

Peters S, Besse B, Marreaud S, et al. 930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIa NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091. *Ann Oncol*. 2022;33:S971-S972. doi:10.1016/j.annonc.2022.07.1056

Provencio-Pulla M, Nadal E, Larriba JLG, et al. Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIa NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial. *J Clin Oncol*. 2022;40(16_suppl):8501. doi:10.1200/JCO.2022.40.16_suppl.8501

Qiu F, Fan J, Shao M, et al. Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial. *J Clin Oncol*. 2022;40(16_suppl):8500. doi:10.1200/JCO.2022.40.16_suppl.8500

Schiller JH. Adjuvant vs. neoadjuvant? What has ASCO 2022 taught us regarding resectable NSCLC? Updated June 27, 2022. Accessed November 3, 2022. <https://www.mdedge.com/hematology-oncology/article/255779/lung-cancer/adjuvant-vs-neoadjuvant-what-has-asco-2022-taught-us>

Glossary

ASCO, American Society of Clinical Oncology

Chemo, chemotherapy

CSS, cancer-specific survival

DFS, disease-free survival

EFS, event-free survival

ESMO, European Society for Medical Oncology

I/O, immunotherapy

ITT, intention-to-treat

MPR, major pathologic response

NSCLC, non-small cell lung cancer

OS, overall survival

pCR, pathologic complete response

PD-1, programmed cell death protein 1

SOC, standard of care